Lion TCR

Lion TCR is a biotech company in Singapore, Singapore. It has raised $60.0M across 2 rounds, most recently a $40.0M Series B in June 2023.

LionTCR | Home

Headquarters
Singapore
Employees
11–50
Total Funding
$60.0M
Last Round
$40.0M Series BJun 2023
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds for this company. The full record is or through the API.

About

Lion TCR develops personalized TCR-T cell therapies that harness patients’ immune systems against viral infections and related cancers, including hepatitis B-related hepatocellular carcinoma. Its approach uses transient receptor expression through mRNA technology to support safety and dose escalation in clinical trials. The company maintains a manufacturing facility for clinical products and conducts trials evaluating the safety and efficacy of its therapies.

Summary

It lists 11–50 employees. It has raised $60.0M in total across 2 rounds, most recently a $40.0M Series B round in Jun 2023.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries B2Jun 2023
$40.0M

Sign up to see all 2 events

Funding: Venture Round through Series B. Amounts, valuations, and investors where available.

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech, Healthcare
Venture RoundTotal funding$884.0MJul 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Lion TCR on Indexed.vc
<a href="https://indexed.vc/companies/lion-tcr"><img src="https://indexed.vc/api/badge/company/lion-tcr" alt="Lion TCR on Indexed.vc" width="260" height="76" /></a>